This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AstraZeneca Encourages Atherosclerosis Education Among High Risk Patients During American Heart Month

WILMINGTON, Del., Feb. 14, 2013 /PRNewswire/ -- A survey conducted by AstraZeneca (NYSE: AZN) of more than 2000 American adults reveals that only 1 in 5 (20 percent) respondents consider themselves at increased risk for atherosclerosis–a progressive disease where plaque builds up in the arteries slowly over time.* The survey also revealed that only 21 percent of respondents could correctly identify all 6 surveyed atherosclerosis risk factors (high cholesterol, high blood pressure, diabetes, family history of early heart disease, smoking and obesity). With these statistics in mind, AstraZeneca is urging Americans to embrace American Heart Month (February) by taking proactive steps to learn more about their health, this disease and whether they may be at risk.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/60010-astrazeneca-atherosclerosis-education-american-heart-month

(Photo:  http://photos.prnewswire.com/prnh/20130214/MM47553-INFO )

This is particularly important because plaque buildup over time can lead to narrowing of the arteries—one of the most common causes of heart disease. For adults living with high cholesterol plus at least one additional risk factor—those who are at increased risk for atherosclerosis—it's even more important to understand which risk factors can be moderated.

"Heart Month is an ideal time for patients to reflect upon their health and talk with their doctor to learn about the risk factors for plaque buildup in arteries and whether they may be at increased risk for atherosclerosis," said Dr. Philip de Vane, Executive Director of Medical Affairs and Strategic Development, AstraZeneca. "This education can be extremely valuable for adults, particularly those who are unaware of their increased risk, and may help mitigate the progression of this disease."

AstraZeneca is committed to helping increase awareness of high cholesterol and other risk factors that can contribute to the progression of atherosclerosis among adults, particularly those at increased risk. They have a number of resources available to consumers who want to learn more about high cholesterol and other risk factors for plaque buildup in arteries, or to get healthy lifestyle tips or questions to ask their doctors. These materials can be accessed by visiting www.CRESTOR.com. One of these resources is the Cholesterol Roadmap, which using the National Cholesterol Education Program guidelines, can help patients to start to identify their LDL-cholesterol goal based on their current health and lifestyle, and develop a list of customized questions for patients to print out and discuss with their physicians along with the initial cholesterol goal assessment.

A cholesterol-management plan to help patients reach their cholesterol goals should begin with lifestyle changes, which can include quitting smoking, eating healthy foods and exercising more often. However, for some people, diet and exercise alone may not be enough to lower high cholesterol, so it is important that they talk with their health care providers about their treatment options.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,927.27 -33.30 -0.20%
S&P 500 1,973.79 -4.55 -0.23%
NASDAQ 4,431.2140 -18.35 -0.41%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs